you are viewing a single comment's thread.view the rest of the posts
Here's their listing of types of attendees:
Managed Care Executives
Outcomes Research Professionals
Medical Affairs Pharmacist
Residents and Fellows
And here's an example from the schedule. AMRN will also participate in The Exchange (see above post):
11:30 am - 12:00 pm Purdue Pharma L.P.
Middle-of-the-Night Awakenings: Matching Insomnia Therapy to Patient Need
Diagnosis and appropriate management of insomnia are important aspects of patient care. Attend the Purdue Pharma L.P. Product Theater “Middle-of-the-Night Awakenings: Matching Insomnia Therapy to Patient Need” to learn about a treatment option now available.
Speaker: Russell Rosenberg, PhD
11:30 am - 12:00 pm Forest Pharmaceuticals, Inc.
This program will evaluate the impact of COPD, review the 2011 GOLD guidelines, discuss goals for improving lung function and present a treatment option for the management of COPD.
Speaker: Shari Fine, DO
12:15 pm - 12:45 pm VIVUS, Inc.
A New Once-Daily Treatment for Obesity
This program will evaluate the impact of obesity on related risk factors and discuss the clinical guidelines and evolving treatment landscape in obesity.
Speaker: Barbara Troupin, MD, MBA
12:15 pm - 12:45 pm AMARIN
Vascepa™: A new therapy for the treatment of severe hypertriglyceridemia
Friday, October 5th
8:30 am - 9:00 am Pfizer Inc
Neuropathic Pain Associated with Spinal Cord Injury
This 30-minute presentation will focus on characterization of neuropathic pain associated with spinal cord injury and its personal and societal burden. Dr. Liss will present clinical trial data and important managed care perspectives. This presentation will include a question-and answer session.
Jonathan L. Liss, MD
Muscogee Manor & Rehabilitation Center
Sentiment: Strong Buy
Tells you that they are moving on different fronts--as fast as they can with limited resources.
Who would give the presentation--would depend on who is avilable.
Joe Zakrzewski wants to make sure that it is done WELL.
VIVUS had 3 months to prepare. Amarin had one month to prepare.
Kay, I second what another poster said (Yahoo will not let me reply directly to his or her post): we hereby nominate Akanz as the speaker. His talk will be called "EPA and the Kiwi - a patient perspective".
Amarin should be seeking him out as their best patient and advocate!
GREAT job--I looked up the program--Saw VIVUS and AMARIN in the same time slot.BOTH offering NEW PRODUCTS.
I put my message while you were replying to my request.
I think this is part of the Launch--Pharmacists would have lot of questions.
Mtd and Kayla
I looked up the Kaiser formularies and Lovaza is not covered ......so if Amarin was to get a favorable co pay listing ...it would be a big deal .
By attending this conference ...shows their marketing is really starting to kick in.